Trial Profile
A 24 Week Off Drug Extension, Parallel Group, Study Assessing Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind, Placebo Controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia (InvestiGAIT Extension)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Bimagrumab (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Acronyms InvestiGAIT Extension
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Jan 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2018 Planned End Date changed from 16 Aug 2019 to 11 Dec 2018.
- 05 Dec 2018 Planned primary completion date changed from 17 Sep 2018 to 11 Dec 2018.